OXALIPLATINE ACCORD 5 mg/ml clinical trials

Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative setting for resectable stage cT2-T4a or N+ gastric and GEJ adenocarcinoma overexpressing FGFR2b (BEMAFLOT)

This study looks at a new combination of a drug called bemarituzumab with standard chemotherapy for stomach and food pipe cancer. It checks how well this new treatment shrinks tumours before surgery in people with a specific type of cancer.